CRMP2 was originally described from a screen for gene mutations affecting axon growth and has been shown to be involved in many neurological disorders, including neuropathic pain, PD, multiple sclerosis, and AD [27–29]. This evidence concerns the gene DPYSL2 and multiple sclerosis.